Klaus Godl

Phenex Pharmaceuticals (Germany) — Germany

Medicine · Health Sciences

21h-index1.8kcitations42works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(10), Chronic Myeloid Leukemia Treatments(8), Advanced Proteomics Techniques and Applications(6), Colorectal Cancer Treatments and Studies(6), HER2/EGFR in Cancer Research(5)

Publications42 total

Data from Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
2023Open Access
Supplementary Table 1 from Cellular Targets of Gefitinib
2023Open Access
Supplementary Methods from Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
2023Open Access
Supplementary Figure 1 from Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
2023Open Access
Supplementary Table 1 from Cellular Targets of Gefitinib
2023Open Access
Supplementary Methods and Figure from Cellular Targets of Gefitinib
2023Open Access
Data from Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
2023Open Access
Supplementary Table 2 from Cellular Targets of Gefitinib
2023Open Access
Data from Cellular Targets of Gefitinib
2023Open Access
Supplementary Figure 1 from Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
2023Open Access
Supplementary Table 2 from Cellular Targets of Gefitinib
2023Open Access
Supplementary Methods and Figure from Cellular Targets of Gefitinib
2023Open Access
Data from Cellular Targets of Gefitinib
2023Open Access
Supplementary Methods from Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
2023Open Access
Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells
Molecular & Cellular Proteomics·2017· 14 citedOpen Access
The broad-spectrum antiinfective drug artesunate interferes with the canonical nuclear factor kappa B (NF-κB) pathway by targeting RelA/p65
Antiviral Research·2015· 50 cited
Abstract LB-325: Global analysis of the phosphoproteome of human blasts reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib
Cancer Research·2014
CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells
Oncogene·2013· 68 cited
Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib
Leukemia·2013· 37 citedOpen Access
Profiling of the kinome of cytomegalovirus-infected cells reveals the functional importance of host kinases Aurora A, ABL and AMPK
Antiviral Research·2013· 42 cited
page 1 of 3Next →

Frequent Co-authors

Henrik Daub(24), Josef Wissing(19), Stephanie Blencke(19), Dirk Brehmer(19), Matthew Cotten(18), Gÿorgý Kéri(16), Stefan C. Müller(16), Michael Weber(14), Andreas Tebbe(11), Alexander Kurtenbach(10), Bert Klebl(10), Christoph Schaab(10), Zoltán Greff(9), Oliver J. Gruß(7), Jan Eickhoff(7), Heidrun Degen(7), László Őrfi(7), Zoltán Horváth(7), Axel Ullrich(7), Martin Klammer(6)